Adaptive Biotechnologies (ADPT) Return on Sales (2018 - 2026)

Adaptive Biotechnologies has reported Return on Sales for 9 years, with the latest figure at 0.01% in Q1 2026.

• Quarterly Return on Sales changed 0.0% year-over-year to 0.01% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 0.01% (changed 0.0% YoY) and the FY2025 annual result came in at 0.0%, up 1.0% from the prior year.
• Return on Sales eased to 0.01% in Q1 2026 per ADPT's latest filing, from 0.0% in the prior quarter.
• Over five years, Return on Sales peaked at 0.0% in Q3 2025 and troughed at 0.06% in Q2 2023.
• A 5-year average of 0.02% and a median of 0.01% in 2024 frame the typical range for Return on Sales.
• The sharpest annual moves came in 2022 and 2023: Return on Sales grew 8 bps in 2022, then decreased 5 bps in 2023.
• Over 5 years, Return on Sales stood at 0.01% in 2022, then plunged by 115 bps to 0.02% in 2023, then surged by 57 bps to 0.01% in 2024, then jumped by 69 bps to 0.0% in 2025, then tumbled by 271 bps to 0.01% in 2026.
• According to Business Quant data, Return on Sales over the past three periods registered 0.01%, 0.0%, and 0.0% for Q1 2026, Q4 2025, and Q3 2025 respectively.